{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper limit of 95% CI were not estimable due to censoring.","groupId":"OG000","lowerLimit":"12.88","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Duration of CR was defined as the time from the date of first dose of study drug or the date of CR to the date of first documentation of PD. CR was defined as negative immunofixation on the serum and urine; soft tissue plasmacytomas disappearance; \\<5% plasma cells (PCs) in bone marrow.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ixazomib 3 mg, capsules, orally, once on Days 1, 8, and 15 for Cycles 1 through 4, during which if the participants tolerated the initial dose, the dose was escalated to ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15 for Cycles 5 through 26, or until documented progressive disease (PD) or intolerable toxicity, whichever occurred first (cycle length=28 days).","id":"OG000","title":"Ixazomib"}],"paramType":"MEDIAN","populationDescription":"Response-evaluable Population included a subset of the Efficacy Population and consisted of all participants who had a baseline\\&at least 1 postbaseline response assessment. As prespecified in the SAP, this population contained only one arm i.e., Ixazomib (efficacy outcomes data for the participants who received placebo before Protocol Amendment 8 was not collected per SAP), thus data is presented accordingly.","reportingStatus":"POSTED","timeFrame":"Up to 58.4 months","title":"Duration of Complete Response (CR)","type":"SECONDARY","unitOfMeasure":"months"}